Capmatinib

What is Capmatinib?[edit]

Capmatinib (Tabrecta) is a kinase inhibitor used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC).

This medicine is indicated to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:

has spread to other parts of the body or cannot be removed by surgery (metastatic), and
whose tumors have an abnormal mesenchymal epithelial transition (MET) gene

An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity.
Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways.
This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein.
c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

Select patients for treatment with Tabrecta based on presence of a mutation that leads to MET exon 14 skipping.

Recommended Dosage

Administration

Take Tabrecta exactly as your healthcare provider tells you.
Take Tabrecta 2 times a day with or without food.
Swallow Tabrecta tablets whole. Do not break, chew, or crush Tabrecta tablets.
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with Tabrecta if you have certain side effects.
Do not change your dose or stop taking Tabrecta unless your healthcare provider tells you to.
If you miss or vomit a dose of Tabrecta, do not make up the dose. Take your next dose at your regular scheduled time.

This medicine is available in fallowing doasage form:

This medicine is available in fallowing brand namesː

Common possible side effects and laboratory abnormalities of this medicine include:

Tabrecta may cause serious side effects, including:

Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Permanently discontinue Tabrecta in patients with ILD/pneumonitis.
May cause hepatotoxicity Monitor liver function tests. Withhold, dose reduce, or permanently discontinue Tabrecta based on severity.
This medicine may cause photosensitivity reactions. Advise patients to limit direct ultraviolet exposure.
Advise patients of the potential risk to a fetus and to use effective contraception.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Safety and effectiveness of Tabrecta in pediatric patients have not been established.

Dispense in the original package with the desiccant cartridge. Store at 20˚C to 25˚C (68˚F to 77˚F), excursions permitted between 15˚C and 30˚C (59˚F and 86˚F).
Protect from moisture.
Discard any unused Tabrecta remaining after 6 weeks of first opening the bottle.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.